Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 5/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | HPGDS | O60760 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3074552 | 1.00 | RECQL (0.41) | RECQLUSP2SMN1; SMN2USP30GPR119 | |
| SCHEMBL3072326 | 0.87 | RECQL (0.42) | RECQLUSP2SMN1; SMN2USP30GPR119 | |
| SCHEMBL3075339 | 0.87 | RECQL (0.42) | RECQLUSP2SMN1; SMN2USP30GPR119 | |
| SCHEMBL3069546 | 0.76 | RECQL (0.43) | RECQLUSP2SMN1; SMN2USP30GPR119 | |
| SCHEMBL3061497 | 0.73 | RECQL (0.41) | RECQLUSP2SMN1; SMN2USP30GPR119 | |
| SCHEMBL3061498 | 0.73 | RECQL (0.41) | RECQLUSP2SMN1; SMN2USP30GPR119 | |
| SCHEMBL24969958 | 0.73 | HPGD (0.51) | RECQLUSP2SMN1; SMN2USP30GPR119 | |
| SCHEMBL13261499 | 0.73 | HPGD (0.51) | RECQLUSP2SMN1; SMN2USP30GPR119 | |
| SCHEMBL16661889 | 0.73 | HPGD (0.51) | RECQLUSP2SMN1; SMN2USP30GPR119 | |
| SCHEMBL1945817 | 0.73 | HPGD (0.51) | RECQLUSP2SMN1; SMN2USP30GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100272680-A1 | Piperidinyl Cyclic Amido Antiviral Agents | BASKARAN SUBRAMANIAN | 2010-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100272680-A1 | Piperidinyl Cyclic Amido Antiviral Agents | ZC3HAV1, MAVS, EIF2AK2 | RECQL 1752/4885USP2 3640/4885SMN1; SMN2 2480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.